• Bruno Caracci, Carolyne Pehora, Lee Benson, Benjamin E Steinberg, Neil M Goldenberg, and Katherine Taylor.
• Department of Anesthesiology and Pain Medicine, The Hospital for Sick Children and The University of Toronto, Ontario, Canada.
• J. Cardiothorac. Vasc. Anesth. 2024 Oct 1; 38 (10): 235623612356-2361.

ObjectivesPulmonary arterial hypertension (PAH) is a devastating complication of pediatric congenital heart disease (CHD). A recent study has identified the protein high mobility group box-1 (HMGB1) as a diagnostic tool in adults with CHD-associated PAH. HMGB1 levels in adults with CHD-associated PAH correlated with mean pulmonary artery pressure and pulmonary vascular resistance, and HGMB1 levels fell in response to sildenafil therapy. We wanted to assess if HGMB1 was a biomarker of pediatric CHD-PAH.DesignProspective cohort study.SettingQuaternary pediatric academic hospital PARTICIPANTS: Children ≤18 years with CHD with and without known pulmonary hypertension. Controls were children undergoing dental or urologic surgery with no known heart disease.InterventionsPulmonary hemodynamics, echocardiographic assessment, and biomarker measurement. Controls had biomarker measurement only.Measurements And Main ResultsPatients with CHD-PAH had mean pulmonary vascular resistance index of 10 Wood units/m2. Neither HGMB1 nor N-terminal pro-brain-type natriuretic peptide levels were significantly different between the groups. Neither marker correlated with pulmonary hypertension.ConclusionsUnlike in adults, HGMB1 is not a biomarker of PAH in pediatric CHD. Further work will continue to explore for biomarkers for this high-risk population.Copyright © 2024 Elsevier Inc. All rights reserved.

33 keywords...

hide…